Beamline Diagnostics raises £650k from Angels in MedCity and Angel Academe to fund clinical trials.
The investment round was led by Angels in MedCity and Angel Academe.
Share allotment filed at Companies House
Beamline Diagnostics develops a rapid biopsy triaging system that screens tissue samples at the point of care. The technology aims to reduce unnecessary pathology lab workloads.
Beamline Diagnostics has secured £650k in a funding round led by Angels in MedCity and Angel Academe alongside other backers. The capital will support further product development and preparations for the company's first in-clinic trials.
Founded by Dr Liberty Foreman and Dr Katherine Willetts, the business has developed the Beamline Solas system, which combines data analysis with existing hardware to screen biopsies at the bedside. The technology is designed to identify healthy samples quickly, reducing the volume of tissue sent to pathology laboratories.
Alongside the funding announcement, the company has appointed Dr Ian Smith as its new chairman. Smith brings extensive clinical trials experience from his previous role at Synexus.
From the founder
"We are really excited to be starting the next phase of BeamLine and initiating our first in-clinic trials. Being part of Angels in Medcity and Angel Academe has offered us such diverse but relevant experience that has and will greatly accelerate our growth."
Liberty Foreman
CEO at Beamline Diagnostics
Use of funds
- 01Continue product development
- 02Fund research and development
Investors
Categories
About the company
Beamline Diagnostics
Beamline Diagnostics develops a rapid point-of-care biopsy screening system.